✦ LIBER ✦

Tyrosine kinase inhibitors in systemic sclerosis: The case for imatinib

✍ Scribed by Flavia V. Castelino; Swati Bhattacharyya; John Varga

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tyrosine kinase inhibitor therapy for sy

✍ Fabian A. Mendoza; Sergio A. Jiménez 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

The role of tyrosine kinase inhibitors i

✍ Başak Koluman; Zeynep Arzu Yegin; Münci Yağcı 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Tyrosine Kinase Inhibitors in the Treatm

✍ Naoki Iwamoto; Jörg H. W. Distler; Oliver Distler 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 146 KB

In-vitro effects of the tyrosine kinase

✍ E. Ranza; G. Mazzini; A. Facoetti; R. Nano 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 375 KB

Effects of imatinib mesylate (Glivec®) a

✍ Yasue Kubota; Suzanne M. Biers; Kenjiro Kohri; Alison F. Brading 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Response of imatinib-resistant extra-abd

✍ Keith M. Skubitz; J. Carlos Manivel; Denis R. Clohisy; Jerry W. Frolich 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 386 KB